Status:
UNKNOWN
Trip-Tox, Effectiveness of Triptans Before and After Onabotulinumtoxin A Treatment in Chronic Migraine
Lead Sponsor:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Conditions:
Chronic Migraine
Eligibility:
All Genders
18-65 years
Brief Summary
Observational, longitudinal, prospective, prospective, comparative study of the effectiveness of triptans before and after onabotulintoxin A initiation in a single group of chronic migraine patients.
Detailed Description
Hypothesis In patients with chronic migraine the efficacy of triptans, previously taken by the patient for the migraine attack, is better and more satisfactory after starting treatment with onabotulin...
Eligibility Criteria
Inclusion
- ICHD-3 criteria for chronic migraine (code 1.3). See Table 3.
- Older than 18 years and younger than 65 years.
- Migraine started in their lifetime before the age of 50 years.
- Migraine of more than one year of evolution since diagnosis.
- Normal cranial CT/MRI study.
- Indication for treatment with Botox
- Taking triptans as a rescue treatment for migraine attacks
Exclusion
- Pregnant women
- Migraine of less than one year of evolution since diagnosis.
- Pathologies that contraindicate the use of OnabotulinumtoxinA (myasthenia gravis, myopathies).
Key Trial Info
Start Date :
March 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 25 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04871152
Start Date
March 25 2021
End Date
September 25 2022
Last Update
October 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Headache and Neuralgia Unit. Neurology Department. Hospital Santa Creu i Sant Pau
Barcelona, Spain